Johnson & Johnson $JNJ Shares Sold by Hikari Power Ltd

Hikari Power Ltd trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 48.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,080 shares of the company’s stock after selling 150,680 shares during the period. Johnson & Johnson makes up 4.7% of Hikari Power Ltd’s investment portfolio, making the stock its 3rd largest holding. Hikari Power Ltd’s holdings in Johnson & Johnson were worth $40,148,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Plato Investment Management Ltd grew its holdings in shares of Johnson & Johnson by 3.9% during the second quarter. Plato Investment Management Ltd now owns 72,416 shares of the company’s stock worth $18,284,000 after purchasing an additional 2,743 shares during the last quarter. Hexagon Capital Partners LLC grew its stake in Johnson & Johnson by 5.3% during the 2nd quarter. Hexagon Capital Partners LLC now owns 5,167 shares of the company’s stock worth $1,312,000 after buying an additional 261 shares during the last quarter. Prospect Financial Group LLC grew its stake in Johnson & Johnson by 3.1% during the 2nd quarter. Prospect Financial Group LLC now owns 2,344 shares of the company’s stock worth $595,000 after buying an additional 70 shares during the last quarter. Roman Butler Fullerton & Co. increased its position in Johnson & Johnson by 0.7% during the second quarter. Roman Butler Fullerton & Co. now owns 11,481 shares of the company’s stock worth $2,959,000 after buying an additional 83 shares during the period. Finally, Simplicity Wealth LLC lifted its stake in Johnson & Johnson by 69.7% in the second quarter. Simplicity Wealth LLC now owns 53,196 shares of the company’s stock valued at $13,510,000 after buying an additional 21,844 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 63,972 shares of company stock worth $16,245,605 over the last three months. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a research note on Wednesday, May 13th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $268.22.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $268.30 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a 50 day simple moving average of $258.88 and a 200-day simple moving average of $243.94. The company has a market cap of $646.58 billion, a price-to-earnings ratio of 31.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.24. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $276.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J’s oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock’s surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.